For the second event, CamNTF will be joined by Dr Xavier Jacq, Head of Biology (MISSION Therapeutics), an experienced drug discovery project manager and expert in protein ubiquitylation and Dr Klaus Okkenhaug, Group Leader (Babraham Institute), an immunologist with particular interests in cell signalling and PI3-kinases. 

Programme:
17.30 Doors open
18.00 PI3K signalling and activated PI3-delta syndrome – Dr Klaus Okkenhaug, Babraham Institute
18.30 DUBs, DUB inhibitors and synthetic lethal screens – Dr Xavier Jacq, MISSION Therapeutics

Attendance is free but all attendees must register in advance, registration closes on 20 April. Places are limited and early registration will be important to avoid disappointment!

If you have a query, please email Dr Tacita Nye.

To learn more about Cambridge New Therapeutics Forum please click here.

For more information click here